Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
about
Positron emission tomography imaging of prostate cancerIdentification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activityCorrelation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesisProstate-specific membrane antigen as a target for cancer imaging and therapyProstate cancer relevant antigens and enzymes for targeted drug deliveryReal-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.Structural characterization of P1′-diversified urea-based inhibitors of glutamate carboxypeptidase IITheragnostic ultrasound using microbubbles in the treatment of prostate cancerProstate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel culturesFunctional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic deviceDiscriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane AntigenGlobal gene expression analysis of reactive stroma in prostate cancer.Non-invasive molecular imaging of prostate cancer lymph node metastasis.Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).Angiogenesis inhibitors in the treatment of prostate cancer.Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers.Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancerA novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.GCPII imaging and cancer.The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy.Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniquesRole of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.Molecular imaging of angiogenesis with SPECT.Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer.Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsTargeted alpha anticancer therapies: update and future prospectsCapture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.
P2860
Q24596241-0836C8EE-4C8C-4C9E-9975-05CBC3710315Q24646415-936DABB9-6FC5-4765-89AD-BF26030BEF9FQ24815250-818D482D-776D-4339-8C97-05E859E6B47BQ26799439-62A09A5A-6E98-49AC-BBE8-A2C218BBD16FQ27013843-E6E13DEE-82B6-4838-9B1B-1DBFFFF4B5C8Q27346788-7322DCF7-4CD0-46E2-B58A-900A2FA873B7Q27683325-89917F4C-A5AB-4D12-9075-CBF9853A9EB4Q28067216-4E6DFD7A-4F5D-4B4F-8FD4-ABBC53F3B63DQ28346048-80464E58-0BC6-43B2-93AF-40CC684D78BEQ28482878-16212FB4-A69F-45CE-8936-A5C21B190063Q28533993-6CCCCE5F-4B79-4901-BA9C-7EA5F67C0AB0Q33464811-CAE9706A-DAAA-412B-B59E-0CDEC4406A57Q33557567-6383CAE6-37D6-4350-BEDD-DA33552B5BFDQ33586706-4415E2ED-BD45-4E05-B6E3-AECC4795CEE4Q33611121-271D3B3B-A80D-4BE5-AA99-2C859E9EEA4AQ33669424-287C776D-4A68-4E62-BE3C-4B643FDC8B4EQ33699158-4556E58C-CACA-496A-82B7-7D9E62C465DAQ33700114-E18D8DA8-2B6B-400A-991B-89A70044AD6CQ33763004-E3C30286-E646-4483-98FA-F99571CA3E90Q33820631-C12EDFA9-D6D6-4BF4-A3D8-C8B0FFF30431Q33827632-429D34A3-890E-4602-8477-F44C07DC5AB9Q33842185-19F966C0-AE52-4EF0-AA6A-C5A3B90A45B0Q33893647-14B29C02-1704-435B-AE6D-365B32C93AA9Q33899288-DD63921A-72C9-4BF0-835F-490B6C0C0969Q33917916-F54B7DC8-9DA2-4C91-9F38-5F66136E9953Q33922507-C953A694-BDB0-42C6-9F1C-693ECE79D832Q33952306-AD37D53C-2C29-4CA0-8343-22660F2061A4Q34040149-C6A43568-13C5-468C-8AED-DEEFCCD3B034Q34241388-3714BA82-9A38-424D-A566-2F0BB44C1738Q34284930-2B1F054D-70DF-48F8-AA47-1B4569871CD6Q34292273-C68B991C-C8AE-4D45-BBC5-F593A70B481CQ34343529-D2FD12BB-B9E8-4869-A88A-89D4C180B4D1Q34344595-863C9CA8-6F94-4EF6-846C-6E3E0E9FF7AEQ34345914-9D144A52-D77D-45C5-B81F-658C7B55F12BQ34485539-2B9AE958-E92B-4016-9505-68C91D9943EFQ34511439-364F485B-70D2-4B18-9074-E668693131DFQ34541981-09DDB36C-427D-4831-A1E0-EA5B2CB78CE6Q34550075-914197B4-9772-4462-B11E-CF8F2316D2E0Q34893030-A3BEDAD4-8AD4-468A-B0DF-5B58EE6D8D21Q35128716-59805CD6-8B22-4EE8-A42A-39762064C03C
P2860
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Five different anti-prostate-s ...... umor-associated neovasculature
@ast
Five different anti-prostate-s ...... umor-associated neovasculature
@en
Five different anti-prostate-s ...... umor-associated neovasculature
@nl
type
label
Five different anti-prostate-s ...... umor-associated neovasculature
@ast
Five different anti-prostate-s ...... umor-associated neovasculature
@en
Five different anti-prostate-s ...... umor-associated neovasculature
@nl
prefLabel
Five different anti-prostate-s ...... umor-associated neovasculature
@ast
Five different anti-prostate-s ...... umor-associated neovasculature
@en
Five different anti-prostate-s ...... umor-associated neovasculature
@nl
P2093
P3181
P1433
P1476
Five different anti-prostate-s ...... umor-associated neovasculature
@en
P2093
L S Grauer
N H Bander
P B Gaudin
V E Reuter
W D Heston
P304
P3181
P407
P577
1999-07-01T00:00:00Z